Abstract
The pharmacological treatment of colorectal tumour leads to MultiDrug Resistance due to overexpression of several ABC transporters such as P-glycoprotein and some Multidrug associated Resistance Proteins (MRPs) that are able to efflux the chemotherapeutic agent out of the cell. A strategy to reverse MDR is the co-administration of antineoplastic agent with a P-glycoprotein inhibitor. These inhibitors are an useful tool for investigating, by PET, the expression and the activity of P-gp and MRPs that are overexpressed in chemoresistant colorectal tumor cells. In this review will be focused the aspect on P-gp and MRPs ligands employed as PET radiotracers considering their pharmacokinetic pharmacodynamic profile and their selectivity towards ABC transporters involved in chemoresistant cell of colorectal tumour.
Keywords: Colorectal, cancer, PET, P-glycoprotein, MultiDrug Resistance, 11-C radiotracers, Everted gut sac, neuroblastoma, epipodophyllotoxins, Nucleotide Binding domains (NBDs)
Current Drug Metabolism
Title: Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Volume: 12 Issue: 10
Author(s): Mariangela Cantore, Elena Capparelli, Francesco Berardi, Roberto Perrone and Nicola Antonio Colabufo
Affiliation:
Keywords: Colorectal, cancer, PET, P-glycoprotein, MultiDrug Resistance, 11-C radiotracers, Everted gut sac, neuroblastoma, epipodophyllotoxins, Nucleotide Binding domains (NBDs)
Abstract: The pharmacological treatment of colorectal tumour leads to MultiDrug Resistance due to overexpression of several ABC transporters such as P-glycoprotein and some Multidrug associated Resistance Proteins (MRPs) that are able to efflux the chemotherapeutic agent out of the cell. A strategy to reverse MDR is the co-administration of antineoplastic agent with a P-glycoprotein inhibitor. These inhibitors are an useful tool for investigating, by PET, the expression and the activity of P-gp and MRPs that are overexpressed in chemoresistant colorectal tumor cells. In this review will be focused the aspect on P-gp and MRPs ligands employed as PET radiotracers considering their pharmacokinetic pharmacodynamic profile and their selectivity towards ABC transporters involved in chemoresistant cell of colorectal tumour.
Export Options
About this article
Cite this article as:
Cantore Mariangela, Capparelli Elena, Berardi Francesco, Perrone Roberto and Antonio Colabufo Nicola, Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer, Current Drug Metabolism 2011; 12 (10) . https://dx.doi.org/10.2174/138920011798062292
DOI https://dx.doi.org/10.2174/138920011798062292 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Review of QSAR for DNA Polymerase Inhibitors and New Models for Heterogeneous Series of Compounds
Current Computer-Aided Drug Design Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry In Silico Study and Cytotoxicity of the Synthesized Open-chain Analogues of Antimycin A3 Against HEP-2 Laryngeal Cancer Cells
Current Cancer Therapy Reviews Hsp90 Affecting Chromatin Remodeling Might Explain Transgenerational Epigenetic Inheritance in Drosophila
Current Genomics Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine An Overview of Olive Oil Biomolecules
Current Biotechnology Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases
Current Drug Metabolism A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design